Crenolanib benzenesulfonate
Based on 18 publication(s) in Google Scholar
Crenolanib benzenesulfonate is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.45%
- CAS No.: 670220-93-6
- Formula: C32H35N5O5S
- Molecular Weight:601.72
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Anti-Blood Cancer Compound Library
HY-L079
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Crenolanib benzenesulfonate
More- Nature. 2025 Jul;643(8071):551-561. [Abstract]
- Cancer Cell. 2025 Apr 14;43(4):740-756.e8. [Abstract]
- Blood. 2018 Jan 25;131(4):426-438. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Cell Rep Med. 2026 Jun 25:102886. [Abstract]
- NPJ Precis Oncol. 2025 Aug 16;9(1):289. [Abstract]
- Stem Cell Res Ther. 2015 Dec 10:6:243. [Abstract]
- J Med Chem. 2019 Mar 14;62(5):2428-2446. [Abstract]
- Glia. 2020 Feb;68(2):345-355. [Abstract]
- Mol Cancer Res. 2022 Feb;20(2):293-304. [Abstract]
- Br J Haematol. 2019 Nov;187(4):488-501. [Abstract]
- BMC Complement Med Ther. 2023 Feb 21;23(1):62. [Abstract]
- Anal Methods. 2025 Nov 27;17(46):9442-9453. [Abstract]
- J Vet Med Sci. 2023 Jul 17;85(7):781-789. [Abstract]
- Hong Kong Polytechnic University. 2025.
- Research Square Preprint. 2021 Nov.
- Patent. US20200129476A1
- bioRxiv. 2019 Jul 1.
Customer Validation & Images
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
WB
-
Cell Imaging/Staining
Biological Activity
Kd: 2.1 nM (PDGFRα), 3.2 nM (PDGFRβ), 0.74 nM (FLT3)
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 670220-93-6
-
Appearance Solid
-
Molecular Weight 601.72
-
Formula C32H35N5O5S
-
Color Off-white to light yellow
-
SMILES
NC1CCN(C2=CC=CC3=C2N=C(N4C5=CC=C(C=C5N=C4)OCC6(COC6)C)C=C3)CC1.O=S(C7=CC=CC=C7)(O)=O
-
Synonyms
CP 868596-26
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8071):551-561. PMID: 40369078 -
Cancer Cell
2025 Apr 14;43(4):740-756.e8. PMID: 40086436 -
Blood
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. [Abstract]2018 Jan 25;131(4):426-438. PMID: 29187377 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Cell Rep Med
GPNMB+ macrophages promote osteogenic differentiation of nucleus pulposus cells through PDGF signaling in intervertebral disc degeneration. [Abstract]2026 Jun 25:102886. PMID: 42349413 -
NPJ Precis Oncol
Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma. [Abstract]2025 Aug 16;9(1):289. PMID: 40819143 -
Stem Cell Res Ther
Platelet-derived growth factor (PDGF)-AA/AB in human serum are potential indicators of the proliferative capacity of human synovial mesenchymal stem cells. [Abstract]2015 Dec 10:6:243. PMID: 26652649
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2015 Dec 10:6:243. [Abstract]
Representative cell morphology. Synovial MSCs were plated at 100 cells/ cm2 and cultured for 10 days in the presence of PDGF isoforms or PDGF receptor (PDGFR) inhibitor (Crenolanib). b Fold increase of synovial MSCs. Data are shown as mean ± SD (n = 9).
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2015 Dec 10:6:243. [Abstract]
Effect of exogenous platelet-derived growth factors (PDGFs) on surface markers of synovial MSCs. Synovial MSCs derived from three donors were plated at 100 cells/cm2 and cultured for 10 days in the presence of PDGF isoforms and PDGF receptor (PDGFR) inhibitor (Crenolanib).
-
J Med Chem
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations. [Abstract]2019 Mar 14;62(5):2428-2446. PMID: 30742435 -
Glia
2020 Feb;68(2):345-355. PMID: 31518022
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: Glia. 2020 Feb;68(2):345-355. [Abstract]
Western blots of PDGFRα and NG2 in slices treated with CP673451 and Crenolanib for 9 days.
-
Mol Cancer Res
GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia. [Abstract]2022 Feb;20(2):293-304. PMID: 34635505 -
Br J Haematol
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. [Abstract]2019 Nov;187(4):488-501. PMID: 31309543 -
BMC Complement Med Ther
Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities. [Abstract]2023 Feb 21;23(1):62. PMID: 36810081
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: BMC Complement Med Ther. 2023 Feb 21;23(1):62. [Abstract]
CCC-ESF-1 Cells were seeded in collagen I-coated plates and treated/not treated with TGFβ1 or PDGF in the presence or absence of Crenolanib (2 μM) for 48 h. Total collagen deposition was visualized by PSR staining.
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: BMC Complement Med Ther. 2023 Feb 21;23(1):62. [Abstract]
CCC-ESF-1 Cells were seeded in collagen I-coated plates and treated/not treated with TGFβ1 or PDGF in the presence or absence of Crenolanib (2 μM) for 48 h. Soluble collagen in the supernatant was detected by the Sircol Soluble Collagen Assay.
Crenolanib benzenesulfonate purchased from MedChemExpress. Usage Cited in: BMC Complement Med Ther. 2023 Feb 21;23(1):62. [Abstract]
CCC-ESF-1 Cells were seeded in collagen I-coated plates and treated/not treated with TGFβ1 or PDGF in the presence or absence of Crenolanib (2 μM) for 48 h. Cytotoxicity was assessed using the lactate dehydrogenase release (LDH) assay.
-
Anal Methods
Developing and validating a sensitive and fast UPLC-MS/MS method for estimating the in vitro metabolic stability of crenolanib in HLMs: identification of structural alarms related to the in silico toxicity and metabolic lability. [Abstract]2025 Nov 27;17(46):9442-9453. PMID: 41246990 -
J Vet Med Sci
Toceranib phosphate (Palladia) reverses type 1 diabetes by preserving islet function in mice. [Abstract]2023 Jul 17;85(7):781-789. PMID: 37258127 -
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (166.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mathias TJ, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr;33(2):300-9. [Content Brief]
[2]. Wang P, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8. [Content Brief]
[3]. Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with STI571-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012, Jun 27. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6619 mL | 8.3095 mL | 16.6190 mL | 41.5476 mL |
| 5 mM | 0.3324 mL | 1.6619 mL | 3.3238 mL | 8.3095 mL | |
| 10 mM | 0.1662 mL | 0.8310 mL | 1.6619 mL | 4.1548 mL | |
| 15 mM | 0.1108 mL | 0.5540 mL | 1.1079 mL | 2.7698 mL | |
| 20 mM | 0.0831 mL | 0.4155 mL | 0.8310 mL | 2.0774 mL | |
| 25 mM | 0.0665 mL | 0.3324 mL | 0.6648 mL | 1.6619 mL | |
| 30 mM | 0.0554 mL | 0.2770 mL | 0.5540 mL | 1.3849 mL | |
| 40 mM | 0.0415 mL | 0.2077 mL | 0.4155 mL | 1.0387 mL | |
| 50 mM | 0.0332 mL | 0.1662 mL | 0.3324 mL | 0.8310 mL | |
| 60 mM | 0.0277 mL | 0.1385 mL | 0.2770 mL | 0.6925 mL | |
| 80 mM | 0.0208 mL | 0.1039 mL | 0.2077 mL | 0.5193 mL | |
| 100 mM | 0.0166 mL | 0.0831 mL | 0.1662 mL | 0.4155 mL |
Crenolanib benzenesulfonate Related Classifications
HY-13223A Related Classifications
Powered by Bioz